Respiratory Exacerbations Increase with Chronic PM$_{2.5}$ Exposure in Current and Former Smokers

James L. Crooks PhD MS[1,2,*], Zhongying Wang MS[3], Morteza Karimzadeh PhD[3], Surya P. Bhatt MD [4], Craig P. Hersh MD, MPH[5], Dawn L. DeMeo MD, MPH[5], David Baraghoshi PhD[1], Min Hyung Ryu PhD[6], Elizabeth A. Regan MD, PhD[7]

1. Division of Biostatistics and Bioinformatics, National Jewish Health
2. Department of Epidemiology, Colorado School of Public Health
3. Department of Geography, Institute of Behavioral Science University of Colorado Boulder
4. Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama Birmingham
5. Channing Division of Network Medicine, Brigham and Women's Hospital & Harvard Medical School
6. Division of Respiratory Medicine, University of British Columbia
7. Division of Rheumatology, Department of Medicine, National Jewish Health

Corresponding Author:
James L. Crooks PhD
Division of Biostatistics and Bioinformatics,
National Jewish Health
1400 Jackson St.
Denver, CO 80206
Email: Crooksj@njhealth.org

Word Count – 2792 of 3500

Author Contributions:
JLC – conception, study design, data analysis, manuscript drafting
ZYW – PM$_{2.5}$ modeling, data generation, geo-coding, data analysis
MK – PM 2.5 modeling, data generation, manuscript review and editing
DAL – data acquisition, interpretation, manuscript review and editing
SPB – data collection, manuscript review and editing
CPH – data collection, manuscript review and editing
DLD – data collection, manuscript review and editing
DB – data analysis, manuscript review and editing
MHR – interpretation, manuscript review and editing
EAR – conception, study design, manuscript drafting

Support: This work was supported by NIEHS grant R21ES032973, NHLBI grants U01 HL089897 and U01 HL089856 and by NIH contract 75N92023D00011. The COPDGene study (NCT00608764) has also been supported by the COPD Foundation through contributions made to an Industry Advisory Committee that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion

Abstract (word count 245)

Rationale: Short-term exposure to fine particulates ($PM_{2.5}$) transiently increases the risk of respiratory exacerbations, but the contribution of chronic, long-term particulate exposure to respiratory exacerbations is poorly defined.

Objectives: To assess long-term effects of $PM_{2.5}$ exposure on risk of severe respiratory exacerbations.

Methods: A longitudinal cohort of current and former smokers with and without COPD were surveyed every six months for severe exacerbation events. $PM_{2.5}$ concentrations at participant addresses were estimated using satellite, reanalysis, and ground-based monitoring data sources.

Measurements and Main Results:

The relative risk of severe exacerbation increased by a factor of 1.516 (CI: 1.226, 1.873; p = 0.00012) for every 10 $\mu g/m^3$ increase in long-term $PM_{2.5}$ exposure across all participants. The effect in the non-COPD participants was greater, with a relative risk of 2.639 (CI: 1.840, 3.756; p<0.0001). Significant effect modifiers with greater effect of $PM_{2.5}$, included prior exacerbations, female sex, and neighborhood characteristics and as well as smoking status, white race, disease severity, asthma diagnosis, and age at enrollment. Significant positive associations for $PM_{2.5}$ on exacerbations were identified at levels below the EPA primary annual standard for $PM_{2.5}$ of 9.0 $\mu g/m^3$.

Conclusions: Persistent exposure to fine particulates is a significant risk factor for severe respiratory exacerbations in current and former smokers, and in patients with or at risk of COPD. The effect of fine particulates on the risk of severe exacerbations appears to be greater in

those current and former smokers without COPD. The EPA annual $PM_{2.5}$ standard may be

inadequate to prevent ongoing lung injury.

Key words (3-5): COPD, air pollution, exacerbations, long-term exposure, $PM_{2.5}$

Background

Heavy cigarette smoking is a well-known risk factor for Chronic Obstructive Pulmonary Disease (COPD) [1], and is associated with extensive burden of disease and increased healthcare costs [2]. However, other inhaled exposures are also commonly associated with both respiratory illness and COPD, including biomass exposure, occupational exposures, and importantly air pollution. Both current and former smokers, as well as never smokers, experience long-term health impacts from air pollution[3]. Ozone, NO_2, and particulate matter with an aerodynamic diameter less than 2.5 microns ($PM_{2.5}$), have adverse effects on health including increased mortality [4,5], cardiovascular disease[6], progression of emphysema and reduced lung function[7], [8,9]. Air pollution, especially its gaseous components, have been linked to risk of COPD incidence, prevalence and progression [1,10,11]. More recent work has defined the importance of small particulates ($PM_{2.5}$) in air pollution that associate with reduced lung function and COPD [11]. An important factor for understanding a potential role for air pollution and COPD disease progression are episodes of respiratory exacerbations from various causes that are associated with disease progression in COPD[12,13]. Severe exacerbations are defined as those that require hospitalization, emergency room visits, and antibiotic and/or steroid treatment. Respiratory exacerbations also impact never-smokers and smokers without COPD, particularly with short term changes in air quality[14,15]. Moreover, the impacts of combined pollutants – ozone, particulates and NO_2 are well documented[16-18], However, the singular role of $PM_{2.5}$ exposure on the risk of acute respiratory exacerbations is less well defined, especially in smokers with a diagnosis of COPD. Further, long- vs short-term exposures to particulates are suggested to have different risks, with evidence of recovery following short-term exposures [19].

Air pollution intensity and constituents vary by location; and an individual's residential location along with severity of local air pollution may be an important social determinant of health related to COPD[20,21]. Determining the sources and impact of various factors on disease risks is critical to improving outcomes of care for COPD and other respiratory diseases. Smoking cessation, for example, is strongly recommended for improved health. Still, persistent exposure to outdoor air pollution may remain as a precipitating factor for exacerbations of disease in both current and former smokers. Other, potentially modifiable factors that affect the risk of exacerbations associated with air pollution are important to define and require detailed individual information as well as the timing and duration of exposures and the impact of specific pollution components. We studied the impact of chronic, local $PM_{2.5}$ concentrations on respiratory exacerbations in a well-characterized established longitudinal cohort of current and former smokers with and without COPD -the COPDGene study, over a period of 16 years (2006-2021). We hypothesized that increased long-term exposure to fine particulate matter would be associated with increased risk of exacerbations. This work was approved by the National Jewish Health Institutional Review Board (HS-3752).

Methods:

Population:

The COPDGene Study enrolled 10,652 individuals at 21 clinical centers around the US who had at least a 10-pack-year history of smoking and the details have been published[22]. The

COPDGene research protocol was approved by the institutional review board at each of the 21 clinical centers, and all participants provided written informed consent. Current residential address was collected from a limited number of the 10,305 participants enrolled in Phase 1 of the study (2007-2012) and the majority of participants in Phase 2. (2012-2017). A small group of never smokers (n=454) were enrolled in Phase 1 and Phase 2 as a control group, and current address was collected from all remaining participants. Thus, a patient's enrollment may have occurred either in Phase 1 or Phase 2. In Phase 3 (2017-2023), updated address information was collected from participants. Jittered patient locations for all phases are visualized in Figure XXX, colored by their enrollment clinical center.

Exacerbations

Participants in COPDGene were surveyed approximately every six months by phone or email, and asked about respiratory exacerbations that resulted in an emergency room visit or hospitalization and was accompanied by treatment with antibiotics and/or glucocorticoids and occurred "since we last spoke". Survey collection started after Phase 1 was initiated, with the first surveys administered in May 2009. A total of 103,017 of these longitudinal follow-ups (LFU) phone surveys were collected from 9,479 participants during our study period ending in December 2021. A total of 6,510 participants had at least one geocoded address and at least one phone survey; this subset of participants had 86,692 unique surveys. Of the 10,652 participants in the COPDGene cohort, a total of 1,573 addresses were obtained in Phase 1, 6,298 addresses in Phase 2, and 4,455 addresses in Phase 3, encompassing 6,719 unique individuals, and geocoded using ArcGIS Pro 2.8.0[23].

Particulate Matter

Daily PM$_{2.5}$ concentrations were previously estimated at a 1km spatial resolution raster over the contiguous U.S. for the years 2005-2021 using a geospatial artificial intelligence (GeoAI) model [24]. These daily concentrations were estimated back approximately eighteen months prior to the beginning of Phase 1 to allow calculation of long-term exposures. The GeoAI model incorporated PM$_{2.5}$ monitor observation, satellite aerosol optical depth (imputed where missing), global reanalysis products, weather data, and elevation. Figure XXX shows the spatial distribution of the 16-year average of the model's daily PM$_{2.5}$ predictions.

A full 16-year time-series of daily PM$_{2.5}$ concentrations was assigned to each participant's geocoded residences using the raster cell into which the residency fell. These concentrations were then averaged over the time intervals between each consecutive pair of surveys. However, following a protocol change on January 1, 2014, whenever a study visit occurred between surveys the average was computed over the interval from the date of the study visit to the date of the survey rather than the interval between the surveys.

Details of how these issues were handled are provided in the supplemental methods. A total of 5,638 participants with 41,735 surveys had at least one assignable PM$_{2.5}$ exposure and were used in the analyses below. Because all time intervals were at least 59 days long, the average PM$_{2.5}$ concentrations are all considered 'long-term exposures' as defined by the U.S. Environmental Protection Agency[25]

Neighborhood Characteristics

Geocoded locations were used to identify US census tracts in which participants lived and thereby derive their tracts' 2018 area deprivation index (ADI)[26], 2018 social vulnerability index (SVI)[27], and neighborhood's Homeowners Loan Corporation (HOLC) grade from the 1930s (i.e., "redlining" grade)[28].

Statistical Analyses

Following geocoding, all subsequent analyses were performed in R version 4.4.2[29].

Crude Model

Associations between the ambient long-term average $PM_{2.5}$ concentrations and self-reported exacerbation counts during the between-survey intervals were estimated using quasi-Poisson models implemented in the gnm[30] package, with a separate fixed stratum intercept for each subject and an offset term accounting for the logarithm of the between-survey interval length. The fixed intercept accounts for all individual-level factors at enrollment including prior medical history (e.g., asthma diagnosis, prior exacerbations) as well as time-invariant factors (e.g., race). A crude model included only strata intercepts and $PM_{2.5}$ as predictors.

Primary Model

Our primary model included these plus potential confounders. Because COPD can be characterized by low blood oxygen levels, the primary model controlled for residence elevation.

Likewise, since COPD tends to be a progressive disease, the primary model also included

nonlinear control for time using linear and quadratic time terms. Model results with p<0.05

were considered 'statistically significant'.

<u>Effect Modification Analyses</u>

To determine whether associations identified in our main model might be impacted by

meteorology, time period, neighborhood and demographic factors, and medical history at

baseline, we explored the modification of the $PM_{2.5}$ effect. Details are provided in the

Supplementary methods.

Furthermore, since the U.S. EPA annual standard for $PM_{2.5}$ is currently 9.0 $\mu g/m^3$, to evaluate

whether the standard is sufficiently protective, the analysis was repeated using only surveys

associated with addresses where the 16-year and between-survey average $PM_{2.5}$ concentrations

were below 9.0, 8.5, 8.0, 7.5, and 7.0 $\mu g/m^3$.

Results

<u>Participants</u>

Demographic characteristics of the cohort at enrollment are given in **Table 1**. The study included

5,638 participants, of whom 2,756 were male and 2,882 female. The racial distribution included

4,123 whites and 1,515 Black/African-Americans. The mean age was 60 years. Most participants

had some college education or were college graduates. On average, participants had a BMI of

28.2, an $FEV_1/height^2$ of 0.83 L/m^2, an FEV_1 and FVC of 2.34 and 3.29 liters, respectively, an

FEV$_1$/FVC of 0.73, a 6-minute walk distance of 1,476 feet, a SGRQ total score of 15, percent emphysema of 2% (% LAA@-950), and a median MMRC dyspnea score of 1.05 with 54% of the participants reporting a score of zero. Smoking characteristics at enrollment found that a small majority were former smokers (50%), with current smokers 43% and never smokers 7%, and 92% had never experienced a severe respiratory exacerbation. In addition, nearly half (44%) were classified as not diagnosed with COPD based on spirometry, which we have termed "GOLD 0". Fewer than half of participants reported a co-morbid disease, with a history of asthma reported in 17%, congestive heart failure 2% and coronary artery disease 6%.

The average number of reported between-survey exacerbations was 0.20 per participant, while the average between-survey interval duration was 205 days. Exacerbation rates were heavily skewed, with median of 0/year, a mean of 0.359/year, and a maximum of 12/year (Supplemental Figure S2). Fully 3630 (64.4%) participants had no exacerbations. The time intervals between surveys were likewise skewed, with a median of 0.556 years (203 days), a mean of 0.647 years (237 days), and a maximum of 10.27 years (3752 days) (Supplemental Figure S2). The average PM$_{2.5}$ concentration between surveys was 8.81 μg/m^3, and the average 16-year PM$_{2.5}$ across surveys was 9.73 μg/m^3. Average ADI and SVI across surveys were both 0.43 on a scale of 0-1. While most geocoded addresses did not fall into a neighborhood with a "redlining" or Homeowners Loan Corporation (HOLC) grade, of those that did, most were in the lowest two grades (C and D). Looking at population characteristics by reported exacerbations, 3630 participants reported no episodes of severe exacerbation, 1337 reported up to one per

year and 671 reported more than 1 per year (**Table 2**). Those who reported any severe

exacerbation had higher (worse) ADI and SVI

Crude and Primary Models

Our crude model estimated a factor of 1.553 (95% CI: 1.293, 1.865; p <0.0001) increase in

exacerbation risk per 10µg/m^3 increase in between-survey average PM$_{2.5}$ concentration.

Our primary model estimated a factor of 1.516 (CI: 1.226, 1.873; p = 0.00012) increase for the

same change in concentration.

Effect Modification Analyses

Table 3 presents our most important effect modification results. The inclusion of linear and

interaction terms for race, gender, GOLD stage, prior severe exacerbations, SVI, and ADI

improved overall model fit based on the likelihood ratio test. Among these, statistically

significant differences were observed between Blacks and whites (p = 0.0001, higher for

Whites), males and females (p = 0.0102, higher for females), prior vs. no prior exacerbations (p

= 0.0016, higher for prior), and between PRISm and GOLD 2 vs. GOLD 0 (p = 0.0011 and p <

0.0001, respectively, higher for GOLD 0 in both cases). Furthermore, in stratified results, GOLD 0

yielded the strongest association with PM$_{2.5}$ (RR = 2.629; 95% CI: 1.840, 3.756; p<0.0001) among

all GOLD stages. Within GOLD 0, former smokers had a stronger PM$_{2.5}$ association (RR = 3.245;

95% CI: 2.030, 1.185; p < 0.0001) than current smokers (RR = 2.015; 95% CI: 1.185, 3.426; p =

0.0097). While smoking status was not statistically significant under the likelihood ratio test, a

statistically significant association was observed among non-current smokers (RR = 1.686; 95%

CI: 1.298, 2.191; $p < 0.0001$). The $PM_{2.5}$ association decreased with increasing ADI. However, while SVI was significant according to the likelihood ratio test, the interaction term itself was not, indicating that the improvement in model fit was driven by the linear term.

Supplemental Table S2 presents further effect modification results. Models with interactions by 16-year average $PM_{2.5}$ ($p = 0.0003$) and age at enrollment ($p < 0.0001$) yielded a significant improvement in model fit based on the likelihood ratio test. Among those, age had a statistically significant interaction coefficient. However, the $PM_{2.5}$ association strengthened with age (Supplemental Figure 7), implying that its improvement in fit was driven by the linear term.

For each continuous modifier, plots of the main $PM_{2.5}$ association over the range of that modifier are given in **Supplemental Figures S4-S13**. These figures show that the association between $PM_{2.5}$ and exacerbations was positive and significant when 16-year average $PM_{2.5}$ fell in the range 2.5–12.5 µg/m^3 (S4), 16-year average daily minimum temperature in the range 3–23 °C (S5), residence elevations below 900 meters (S6), SVI below 0.85 (S7), ADI below 0.55 (S8), age at enrollment above 55 years (S9), FEV_1/height^2 above 0.5 L/m^2 (S10), % emphysema below 27% (S11), pack years below 75 (S12), and BMI between 20 and 50 (S13).

Among categorical modifiers (**Supplemental Table S2**), statistically significant differences were observed between 2014 or earlier vs. 2015-2018 ($p = 0.0089$, higher for 2015-2018) and HOLC grade A vs. D ($p = 0.0027$, higher for grade D). These results indicate that the exacerbation risk associated with $PM_{2.5}$ was higher for participants who were white and female, those with prior

exacerbations and less smoking history and disease progression at enrollment, those who were older at enrollment, and those living in neighborhoods with less deprivation now but with more historical disinvestment.

<u>Sensitivity Analyses</u>

Supplemental Table S3 presents sensitivity results. Associations remained positive under all sensitivity analyses except the model with linear control for time, with risk ratios for the other analyses ranging from 1.263 to 1.561 per $10\mu g/m^3$ increase in $PM_{2.5}$. The binomial model analyzing presence or absence of exacerbations yielded an odds ratio of 2.097 (95% CI: 1.542, 2.851; $p < 0.0001$), while the mixed effects model yielded a risk ratio of 1.463 (95% CI: 1.167, 1.832; $p = 0.0009$) for the same exposure change. Using only surveys with short interval periods had no qualitative impact on the result (**Supplemental Figure S14**). Using only surveys taken while subjects lived at residences with 16-year average $PM_{2.5}$ below the current standard yielded a statistically significant positive associations below 9 $\mu g/m^3$, 8.5 $\mu g/m^3$, and 8.0 $\mu g/m^3$ (Supplemental Figure S15). Using only surveys with between-survey average $PM_{2.5}$ below the current standard yielded a statistically a significant positive association below 9 $\mu g/m^3$ (Supplemental Figure S16).

Discussion

We estimated a positive association between $PM_{2.5}$ exposure and severe exacerbation risk, corresponding to a 51.6% increase in risk for each 10 $\mu g/m^3$ increase in $PM_{2.5}$. In addition, we found that the exacerbation risk driven by $PM_{2.5}$ exposure tended to be higher among

populations considered less sensitive or vulnerable in some ways (whites, patients living in less deprived areas, and patients with little disease progression) and more sensitive or vulnerable in other ways (females, older patients, patients with prior exacerbation history, patients living in historically disinvested areas, patients with moderate disease progression). Participants without spirometric obstruction (GOLD 0) at enrollment had the strongest $PM_{2.5}$ association among all subgroups, and, within that group, the former smokers had a stronger association than current smokers. No subgroup of participants had a protective association with $PM_{2.5}$ except the small number (N = 84) living in HOLC grade A neighborhoods. We found little evidence that $PM_{2.5}$ mediates the impact of prior exacerbation history on future exacerbations.

Our mixed results in terms of vulnerability or susceptibility factors belie the complexity of real-world multi-domain exposures through the life course and their potentially countervailing impacts on COPD patients' sensitivity to air pollution. This work is the first to study the impact of $PM_{2.5}$ on respiratory exacerbations in a well-characterized COPD cohort of this size and opens the door to future studies investigating $PM_{2.5}$ associations with lung imaging measures and molecular endpoints, as well as multi-pollutant impacts.

This work has several limitations. First, because addresses were collected on different days than the phone surveys, we necessarily made an assumption regarding when participants moved between residences in order to assign exposures to between-survey intervals. We explored a different assumption in a sensitivity analysis, but other assumptions are possible. Second, exposures were estimated not measured, so errors in our $PM_{2.5}$ estimates may affect our

results; however, the error involved is of the Classical type, which usually yields associations that are less strong than the true association. Furthermore, modeling work on other outcomes has shown that using $PM_{2.5}$ estimated with error yields results similar to the truth[31].

Beyond potential clinical importance, our results have regulatory implications. A significant positive association was observed in areas with 16-year average $PM_{2.5}$ concentrations below 8.0 $\mu g/m^3$, which is below the current U.S. EPA $PM_{2.5}$ level annual standard, and a significant positive association was also observed when using only between-survey average concentrations below the standard. This indicates that, at least in the population studied here, the standard may insufficient to protect public health. Moreover, the regulation of $PM_{2.5}$ is largely justified based on its relationships with mortality and cardiovascular health effects, not respiratory health effects, so demonstrating a respiratory health effect due to long-term $PM_{2.5}$ exposure further increases the evidence basis for standard setting.

Figure 1. Population Locations and PM2.5 Concentrations.
Map of geocoded participant residence locations for all phases overlaid on 16-year average PM2.5 concentrations from the GeoAI model. Residence locations have been jittered to protect privacy. Participant locations are color coded by the COPDGene cinical site at enrollment, though in some cases participants move between phases.

Table 1. Population Characteristics

Characteristic		Percent (n), Median (quartile 1, quartile 3) or Mean (SD)
Number = 5638		
Age years		60 (53, 66)
Sex	Male: 49% (2756), Female: 51% (2882)	
Race	NHW: 73% (4123), AA:27% (1515)	
BMI		28.2 (24.7, 32.3)
Education	8th grade or less	1.5% (87)
	High school – no diploma	8% (453)
	High school graduate	22% (1240)
	Some college	27% (1537)
	College graduate	29% (1615)
	Master's or doctoral degree	13% (706)
Income	< $15,000	17% (939)
	$15,000 - $35,000	20% (1109)
	$35,000- $50,000	13% (708)
	$50,000 -$75,000	13% (768)
	More than $75,000	14% (768)
	Decline to answer	25% (1383)
FEV_1 (L)*		2.34 (1.75, 2.94)
FVC (L)*		3.29 (2.67, 4.03)
FEV_1/FVC*		0.73 (0.63, 0.80)
FEV_1/height^2 *		0.83 (0.64, 0.99)
GOLD Stage*	GOLD 0	44% (2464)
	GOLD 1	8% (468)
	GOLD 2	18% (1030)
	GOLD 3	9% (518)
	GOLD 4	2% (135)
	PRISm	11% (641)
	Never smoker	6% (360)
Comorbidities	Asthma	17%
	Coronary artery disease	6%
	Congestive heart failure	2%
SGRQ		15 (4, 35)
Percent emphysema	Percent LAA@-950	2 (1, 6)
Smoking status	Current	43% (2419)
	Former	50% (2839)

	Never	7% (380)
Pack years smoking		37 (23, 51)
History of severe exacerbation		8% (462)
Six-minute walk distance		1476 (1230, 1700)
MMRC Dyspnea score	Score $\geq$ 1: 46% (2616)	No dyspnea: 54% (3013)
Area Deprivation Index (ADI)	range 0-1	0.43 (0.28)
Social Vulnerability Index (SVI)	range 0-1	0.43 (0.25)
Redlining (HOLC) grade by events	D (worst) - 8% (3199), C- 10% (4306), B - 6% (2563), A- 1% (495, No redlining value - 75% (31,172)	
16-year average PM2.5 (μg/m^3)		9.73 (1.54)

* 22 participants failed spirometry and have missing values

Table 2. Characteristics and Exposures by Exacerbation Rates

Characteristic	Exacerbations		
	None	0-1 per year	> 1 per year
Average PM 2.5 exposure (μg/m^3)	8.85 (1.52	8.80 (1.39)	8.95 (1.64)
Age	60 (9)	61 (8)	59 (9)
Sex (% male)	52%	42%	45%
Race (% NHW)	72%	78%	69%
Smoking status			
Current	43%	41%	47%
Former	48%	56%	53%
Never	9%	3%	2%
ADI	0.44 (0.25)	0.44 (0.25)	0.47 (0.25)
SVI	0.47 (0.28)	0.46 (0.28	0.54 (0.28)

Table 3. Effect Modifiers

Modifier	Likelihood ratio test p-values	Interactions			Point values		
		Comparison	Estimate (95% CI)*	p-value	Category	Estimate (95%CI)*	p-value
Race	**0.0001**	**Black vs White**	**0.420 (0.271, 0.652)**	**0.0001**	**White (N=4123)**	**1.838 (1.458, 2.318)**	**<0.0001**
					Black (N=1515)	0.772 (0.516, 1.165)	0.21
Sex	**0.0102**	**Female vs Male**	**1.657 (1.127, 2.435)**	**0.0103**	Male (N=2756)	1.103 (0.799, 1.524)	0.55
					Female (N=2882)	**1.828 (1.417, 2.357)**	**<0.0001**
Smoking status^	0.32	Former vs Current	0.756 (0.517, 1.107)	0.1505	Current (N=2419)	1.275 (0.933, 1.743)	0.1268
		Never vs Current	1.339 (0.235, 7.643)	0.7424	**Former (N=2839)**	**1.686 (1.293, 2.191)**	**<0.0001**
					Never (N=380)	2.258 (0.403, 12.65)	0.35
GOLD Stage^	**0.0003**	**PRISm vs GOLD 0**	**0.343 (0.180, 0.652)**	**0.0011**	**GOLD 0 (N=2464)**	**2.629 (1.840, 3.756)**	**<0.0001**
		GOLD 1 vs GOLD 0	0.503 (0.218, 1.159)	0.1067	PRISm (N=641)	0.901 (0.516, 1.573)	0.7143
		GOLD 2 vs GOLD 0	**0.339 (0.204, 0.562)**	**<0.0001**	GOLD 1 (N=468)	1.322 (0.614, 2.849)	0.4743
		GOLD 3 vs GOLD 0	0.764 (0.448, 1.305)	0.3252	GOLD 2 (N=1030)	0.890 (0.607, 3.032)	0.5508
		GOLD 4 vs GOLD 0	0.468 (0.199, 1.102)	0.0824	**GOLD 3 (N=518)**	**2.010 (1.319, 3.032)**	**0.0012**
					GOLD 4 (N=135)	1.231 (0.560, 2.704)	0.6054
		Never smokers vs GOLD 0	0.898 (0.141, 5.734)	0.9098	Never smokers (N= 360)	2.362 (0.388, 14.58)	0.3546
Prior severe exacerbation^	**0.0016**	**Yes vs No**	**2.085 (1.324,3.286)**	**0.0015**	**No (N= 5176)**	**1.314 (1.044, 1.655)**	**0.0199**
					Yes (N=462)	**2.74 (1.798, 4.180)**	**<0.0001**
SVI	0.0094		0.759 (0.386,1.494)	0.4246			
ADI	0.0052		**0.312 (0.152, 0.639)**	**0.0014**			

* Per 10 $\mu g/m^3$ increase in PM $_{2.5}$

^ evaluated at enrollment

References

1. Sin DD, Doiron D, Agusti A, et al. Air pollution and COPD: GOLD 2023 committee report. *European Respiratory Journal*. 2023-05-11 2023;61

2. Boers E, Barrett M, Su JG, et al. Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. *JAMA Netw Open*. Dec 1 2023;6(12):e2346598. doi:10.1001/jamanetworkopen.2023.46598

3. Manisalidis I, Stavropoulou E, Stavropoulos A, Bezirtzoglou E. Environmental and Health Impacts of Air Pollution: A Review. *Front Public Health*. 2020;8:14. doi:10.3389/fpubh.2020.00014

4. Hao Y, Balluz L, Strosnider H, Wen XJ, Li C, Qualters JR. Ozone, Fine Particulate Matter, and Chronic Lower Respiratory Disease Mortality in the United States. *Am J Respir Crit Care Med*. Aug 1 2015;192(3):337-41. doi:10.1164/rccm.201410-1852OC

5. Samet JM, Dominici F, Curriero FC, Coursac I, Zeger SL. Fine particulate air pollution and mortality in 20 U.S. cities, 1987-1994. *The New England journal of medicine*. Dec 14 2000;343(24):1742-9. doi:10.1056/NEJM200012143432401

6. Peters A, Dockery DW, Muller JE, Mittleman MA. Increased particulate air pollution and the triggering of myocardial infarction. *Circulation*. Jun 12 2001;103(23):2810-5. doi:10.1161/01.cir.103.23.2810

7. Wang M, Aaron CP, Madrigano J, et al. Association Between Long-term Exposure to Ambient Air Pollution and Change in Quantitatively Assessed Emphysema and Lung Function. *JAMA : the journal of the American Medical Association*. Aug 13 2019;322(6):546-556. doi:10.1001/jama.2019.10255

8. Thi Khanh HN, De Troeyer K, Smith P, Demoury C, Casas L. The impact of ambient temperature and air pollution on SARS-CoV2 infection and Post COVID-19 condition in Belgium (2021-2022). *Environ Res*. Dec 29 2023;246:118066. doi:10.1016/j.envres.2023.118066

9. Kalluci E, Noka E, Bani K, et al. Correlation between COVID-19 and air pollution: the effects of PM2.5 and PM10 on COVID-19 outcomes. *Eur Rev Med Pharmacol Sci*. Dec 2023;27(6 Suppl):39-47. doi:10.26355/eurrev_202312_34688

10. Park J, Kim HJ, Lee CH, Lee CH, Lee HW. Impact of long-term exposure to ambient air pollution on the incidence of chronic obstructive pulmonary disease: A systematic review and meta-analysis. *Environ Res*. Mar 2021;194:110703. doi:10.1016/j.envres.2020.110703

11. Doiron D, de Hoogh K, Probst-Hensch N, et al. Air pollution, lung function and COPD: results from the population-based UK Biobank study. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology*. Jul 2019;54(1)doi:10.1183/13993003.02140-2018

12. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. *Respiratory care*. Dec 2003;48(12):1204-13; discussion 1213-5.

13. Bhatt SP, Bodduluri S, Dransfield MT, et al. Acute Exacerbations Are Associated with Progression of Emphysema. *Annals of the American Thoracic Society*. Dec 2022;19(12):2108-2111. doi:10.1513/AnnalsATS.202112-1385RL

14. Ross BA, Doiron D, Benedetti A, et al. Short-term air pollution exposure and exacerbation events in mild to moderate COPD: a case-crossover study within the CanCOLD cohort. *Thorax*. Oct 2023;78(10):974-982. doi:10.1136/thorax-2022-219619

15.   Doiron D, de Hoogh K, Probst-Hensch N, et al. Residential Air Pollution and Associations with Wheeze and Shortness of Breath in Adults: A Combined Analysis of Cross-Sectional Data from Two Large European Cohorts. *Environmental health perspectives*. Sep 29 2017;125(9):097025. doi:10.1289/EHP1353

16.   Choo ELW, Janhavi A, Koo JR, Yim SHL, Dickens BL, Lim JT. Association between ambient air pollutants and upper respiratory tract infection and pneumonia disease burden in Thailand from 2000 to 2022: a high frequency ecological analysis. *BMC Infect Dis*. Jun 6 2023;23(1):379. doi:10.1186/s12879-023-08185-0

17.   Wilgus ML, Merchant M. Clearing the Air: Understanding the Impact of Wildfire Smoke on Asthma and COPD. *Healthcare (Basel)*. Jan 25 2024;12(3)doi:10.3390/healthcare12030307

18.   Jung YJ, Kim EJ, Heo JY, Choi YH, Kim DJ, Ha KH. Short-Term Air Pollution Exposure and Risk of Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Korea: A National Time-Stratified Case-Crossover Study. *International journal of environmental research and public health*. Feb 28 2022;19(5)doi:10.3390/ijerph19052823

19.   Guo C, Zhang Z, Lau AKH, et al. Effect of long-term exposure to fine particulate matter on lung function decline and risk of chronic obstructive pulmonary disease in Taiwan: a longitudinal, cohort study. *Lancet Planet Health*. Mar 2018;2(3):e114-e125. doi:10.1016/S2542-5196(18)30028-7

20.   Jbaily A, Zhou X, Liu J, et al. Air pollution exposure disparities across US population and income groups. *Nature*. Jan 2022;601(7892):228-233. doi:10.1038/s41586-021-04190-y

21.   Levy JI, Quiros-Alcala L, Fabian MP, Basra K, Hansel NN. Established and Emerging Environmental Contributors to Disparities in Asthma and Chronic Obstructive Pulmonary Disease. *Curr Epidemiol Rep*. Jun 2018;5(2):114-124. doi:10.1007/s40471-018-0149-9

22.   Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. *Copd*. Feb 2010;7(1):32-43. doi:10.3109/15412550903499522

23.   *ArcGIS Pro*. Version 2.8.0. Esri (Environmental Systems Research Institute);

24.   Wang Z, Crooks JL, Regan EA, Karimzadeh M. High-Resolution Estimation of Daily PM2.5 Levels in the Contiguous US Using Bi-LSTM with Attention. *Remote Sensing*. 2025;17(1). doi:10.3390/rs17010126

25.   Agency" EP. Regulatory Impact Analysis for the Proposed Reconsideration of the National Ambient Air Quality Standards for Particulate Matter. In: Agency EP, editor.: National Service Center for Environmental Publications (NSCEP); 2022. p. 467.

26.   Kind AJH, Buckingham WR. Making Neighborhood-Disadvantage Metrics Accessible - The Neighborhood Atlas. *The New England journal of medicine*. Jun 28 2018;378(26):2456-2458. doi:10.1056/NEJMp1802313

27.   CDC/ATSDR Social Vulnerability Index 2019 Database (2020).

28.   Nelson RK, Winling L. Mapping Inequality: Redlining in New Deal America. Accessed 10/05/2023. https://dsl.richmond.edu/panorama/redlining

29.   R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Accessed 13 Aug 2018, https://www.R-project.org/

30.   Turner H, Firth D. *Generalized nonlinear models in R: An overview of the gnm package*. 2020. https://cran.r-project.org/package=gnm

31.   Wei Y, Qiu X, Yazdi Mahdieh D, et al. The Impact of Exposure Measurement Error on the Estimated Concentration–Response Relationship between Long-Term Exposure to PM2.5 and Mortality. *Environmental health perspectives*. 130(7):077006. doi:10.1289/EHP10389